ED Observation for Opioid Use Disorder

N/AActive Not RecruitingNCT05064826

NYU Langone Health170 enrolled

Overview

This is a multicenter, randomized clinical comparative effectiveness trial (RCT) in which patients with untreated OUD presenting to a Northwell Health Emergency Department (ED), NYULH-Brooklyn, NYULH-Tisch, and Bellevue Hospital will be randomized (1:1) to be managed clinically through either a standard ED visit or an extended visit through ED observation (EDOU).

In this hybrid implementation-effectiveness study, there is no direct research intervention. Rather, clinical care with well-documented effectiveness will be delivered at the discretion of clinical staff guided by clinical protocols for the management of OUD with MOUD (Medications for Opioid Use Disorder) introduced at each site prior to study enrollment. Enrolled patients will be randomized to ED vs. EDOU and to participate in assessments conducted at the index visit and at 30 days and 90 days. Patient level data will also be matched with Medicaid claims data for more robust analyses and to support the development of clinical quality measures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

170

Conditions

Opioid Use Disorder

Interventions

ObservationOTHER

Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED. Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Is 18 years of age or older * Is able to speak English sufficiently to understand study procedures * Has a history of non-medical opioid use * Is a potential candidate for ED-based MOUD treatment initiation and referral at the site as confirmed by clinical staff * s not receiving MOUD through ongoing formal addiction treatment or pain management at the time of index ED visit * Is willing to receive either standard ED care or enhanced ED care in EDOU depending on random assignment * Presents to the ED during study screening hours Exclusion Criteria: * Unwilling or unable to provide written/electronic informed consent/HIPAA Authorization for research procedures, including research visits at baseline and Day 30 and Day 90, and/or consent for the release of health records and data matching for a period of 2 years following enrollment and 1 year prior to enrollment. * Currently in jail, prison or any inpatient overnight facility as required by court of law or have pending legal action or that could prevent participation in the study * Presents from a medical-based extended care facility (e.g., skilled nursing facility) * Previous participation in the current study * Inadequate locator information (unable or unwilling to provide one unique mean of contact). * Has acute, severe medical, psychiatric, or concurrent substance use problem or meets other criteria that would exclude the patient (clinically) from placement in EDOU according to EDOU placement clinical protocols.

Locations (6)

Rutgers University-University Hospital

Newark, New Jersey, United States

NYULH-Brooklyn

Brooklyn, New York, United States

Northwell Health - Long Island Jewish Medical Center

New Hyde Park, New York, United States

Bellevue

New York, New York, United States

Outcomes

Primary Outcomes

Proportion of participants who receive Emergency Department (ED)-initiated Buprenorphine (BUP)

Receipt of ED-initiated BUP will be operationally defined to include administration of BUP and/or prescription for BUP as part of the ED/Emergency Department Observation (Units) (EDOU) visit. This measure will be abstracted from the health record primarily.

Time frame: Week 1 (~7-10 days)

Proportion of participants who receive ED-initiated or ED-expedited BUP

Receipt of ED-initiated/expedited BUP will be operationally defined to include the provision of a specific "warm" referral or transfer of care to a provider, clinic, or treatment setting with the capacity to administer and/or prescribe BUP within 24 hours of completion of the ED/EDOU visit. Eligible transition of care will be will described further in the Manual of Operations (MOP) and will include direct transport or handoff to an outpatient provider immediately from the ED, provision of an appointment within 24 hours (with a specific time and location), transfer to general inpatient or inpatient OUD/addiction treatment. Neither confirmation of a completed appointment (i.e., patient shows up and is seen) nor receipt of BUP at the dedicated follow-up appointment will be required as the patient and treating provider may elect to treat with alternative regimes (e.g., methadone, naltrexone). This measure will be abstracted from the health record primarily.

Time frame: Week 1 (~7-10 days)

Proportion of participants who receive ED-initiated or ED-expedited Medications for Opioid Use Disorder (MOUD)

Receipt of ED-initiated MOUD, inclusive of BUP, methadone, or naltrexone.

Time frame: Week 1 (~7-10 days)

The proportion of participants who are successfully linked to formal addiction treatment within one week following the completion of their index ED/EDOU visit

Successful linkage to formal addiction treatment will be defined as confirmed attendance at formal addiction treatment for OUD following completion of the ED/EDOU visit. Formal addiction treatment will be those treatments consistent with the American Society of Addiction Medicine's (ASAM) level of care (1-4) and will include a range of clinical settings, including office-based providers of BUP or naltrexone, Opioid Treatment Programs (OTPs), intensive outpatient, inpatient, or residential treatments. Means of confirmation will include direct contact with the facility and/or treating clinician or other objective means (e.g., medical record review).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Change in number of days of opioid and other drug use

Measured by the Timeline Follow-Back (TLFB) procedure will be used to elicit the participant's self-reported use of illicit substances at baseline and throughout study participation.

Time frame: Baseline, Day 30

Change in number of days of opioid and other drug use

Measured by the Timeline Follow-Back (TLFB) procedure will be used to elicit the participant's self-reported use of illicit substances at baseline and throughout study participation.

Time frame: Day 30, Day 90

Change in proportion of participants who tested positive for illicit opioids/substances

Time frame: Baseline, Day 30

Change in proportion of participants who tested positive for illicit opioids/substances

Time frame: Day 30, Day 90

Change in number of overdose events and risk behaviors

Time frame: Baseline, Day 30

Change in number of overdose events and risk behaviors

Time frame: Day 30, Day 90

Change in score on EuroQol-5 Dimensions (EQ-5D) Scale

EuroQol-5 Dimensions (EQ-5D): The EuroQol is a structured interview that collects general health information applicable to a wide range of health conditions and treatment, providing a simple descriptive profile and a single index value for health status between 0 (dead) and 1 (full health).

Time frame: Baseline, Day 30

Change in score on EuroQol-5 Dimensions (EQ-5D) Scale

Time frame: Day 30, Day 90

Change in Score on Patient-Reported Outcomes Measurement Information System (PROMIS-29) Scale

Assessment of quality of life in seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) all assessed using the PROMIS-29 questionnaire. PROMIS-29 is scored on a T-score metric with a mean of 50 and a standard deviation of 10 in the U.S. general population, with a higher score representing more symptoms.

Time frame: Baseline, Day 30

Change in Score on Patient-Reported Outcomes Measurement Information System (PROMIS-29) Scale

Time frame: Day 30, Day 90

Change in score on Patient Health Questionnaire (PHQ)-9 Scale

The PHQ-9 is a 9-item instrument used for screening, diagnosing, monitoring and measuring the severity of depression. Each item is rated from 0 (not at all) to 3 (nearly every day). Total scores range from 0-27. Scores are interpreted as follows: Minimal Depression: 0-4, Mild depression: 5-9, Moderate depression: 10-14, Moderately severe depression: 15-19, Severe depression: 20-27.

Time frame: Baseline, Day 30

Change in score on Patient Health Questionnaire (PHQ)-9 Scale

Time frame: Day 30, Day 90

Change in score on Treatment Effectiveness Assessment (TEA) Scale

Treatment Effectiveness Assessment (TEA) scale is comprised of 4 questions about substance use, health, lifestyle, and community. Participants respond the questions on how they have improved in that area on a scale from 1 (not better at all) to 10 (very much better). Higher scores indicate overall improvement and effectiveness of treatment.

Time frame: Baseline, Day 30

Change in score on Treatment Effectiveness Assessment (TEA) Scale

Time frame: Day 30, Day 90

Change in proportion of participants who reported treatment satisfaction

Time frame: Baseline, Day 30

Change in proportion of participants who reported treatment satisfaction

Time frame: Day 30, Day 90

Change in proportion of participants who reported changes in social determinants of health (e.g., homelessness, employment)

Self reported by participants.

Time frame: Baseline, Day 30

Change in proportion of participants who reported changes in social determinants of health (e.g., homelessness, employment)

Self reported by participants.

Time frame: Day 30, Day 90